Envista Holdings Corporation (NVST) Q3 2024 Earnings Conference Call Transcript Summary
Envista Holdings Corporation (NVST) Q3 2024 Earnings Conference Call Transcript Summary
Adjusted diluted EPS for Q3 was $0.12, compared to $0.43 in Q3 of 2023.The following is a summary of the Envista Holdings Corporation (NVST) Q3 2024 Earnings Conference Call Transcript:
以下是 Envista Holdings 公司 (NVST) 2024年第三季度業績會電話會議記錄摘要:
Financial Performance:
金融業績：
Reported Q3 2024 revenue of $601 million, a decline of 5.3% year-over-year, primarily due to the larger Spark revenue deferral and channel inventory reductions.
Adjusted EBITDA margin decreased to 9.1%, reflecting a decline of 10.5 percentage points year-over-year, mainly driven by the Spark revenue deferral change and investment in growth.
Adjusted diluted EPS for Q3 was $0.12, compared to $0.43 in Q3 of 2023.
Generated $63 million in free cash flow during the quarter.
報告2024年第三季度營業收入爲60100萬美元，同比下降5.3%，主要是由於更大的 Spark 收入遞延和渠道庫存減少所致。
調整後的EBITDA利潤率下降到9.1%，同比下降10.5個百分點，主要受到Spark收入遞延變化和對增長的投資的影響。
2024年第三季度調整後每股收益爲0.12美元，而2023年第三季度爲0.43美元。
本季度自由現金流爲6300萬美元。
Business Progress:
業務進展：
Announced significant investments in product development and commercial capabilities, especially in Nobel and orthodontics, to close the growth gap in North America and globally.
Gained market share in orthodontics and diagnostics, while maintaining market position in consumables.
Launched new diagnostic offerings including a CBCT platform, enhanced software for DEXIS intraoral scanner, and additional functionality in DTX treatment planning.
Introduced measures to reduce channel inventory, aligning sell-in more closely with end-customer demand.
宣佈在產品開發和商業能力方面進行重大投資，特別是在 Nobel 和正畸學上，以填補在北美和全球的增長差距。
在正畸和診斷方面獲得市場份額，同時保持耗材的市場地位。
推出了包括CBCt平台、DEXIS口腔內掃描儀增強軟件以及DTX治療計劃中的額外功能在內的新診斷產品。
引入措施以減少渠道庫存，使賣出更加緊密地與最終客戶需求相一致。
Opportunities:
機會：
Expecting to return to growth on a reported basis in Q4, projecting continued improvements from strategic growth investments and product innovations.
預計在Q4報告基礎上實現增長，預計從戰略性增長投資和產品創新中持續改善。
Risks:
風險：
Continued deferral of Spark revenue impacting current revenue figures, although mitigated somewhat in Q4 and expecting recovery over the next 18 months.
Reduction in channel inventory contributing to a decrease in reported sales, foreseeing a normalization of inventory levels in the near future.
持續推遲Spark營收影響當前收入數字，儘管在Q4中有所緩解，並預計在未來18個月內恢復。
渠道庫存的減少導致報告銷售額下降，預見未來不久將庫存水平正常化。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
